Fig 3.

Kaplan-Meier estimated progression-free survival (PFS) curves by biomarker status. (A) PFS for unselected patients in the intent-to-treat population (seribantumab [S] + paclitaxel [P] v P). (B) PFS for control arm patients in the biomarker (BM) –evaluable population (P alone; BM positive [pos] v BM negative [neg]). (C) PFS for BM-pos patients in the BM-evaluable population (S + P v P). (D) PFS for BM-negative patients in the BM-evaluable population (S + P v P). BM pos, heregulin (HRG) score ≥ 1 and human epidermal growth factor receptor 2 (HER2) < 126,000 receptors per cell); BM neg, HRG score < 1 and/or HER2 ≥ 126,000 receptors per cell. HR, hazard ratio.